KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 3

General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience

Ümmühan ABDULREZZAK
Mevlüde İNANÇ
Şebnem GÜRSOY
Hüseyin DURSUN
Ender DOĞAN
Metin ÖZKAN
Erdoğan SÖZÜER
Fahri BAYRAM
Figen ÖZTÜRK
Gülten Can SEZGİN
Alper YURCİ
Sayfa
347–352
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Age is an independent prognostic factor that affecting survival in carcinoid syndrome patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Carcinoid syndrome is one of the functional neuroendocrin tumor symptom.
📊
Temel Bulgular & Veri:Kaplan Meier method was used for overall survival.Results: Among 450 patients diagnosed neuroendocrine tumor in our hospital, 29 of them (6.4%) were presented withcarcinoid syndrome.
💡
Sonuç & Katkı:Age is an independent prognostic factor that affecting survival in carcinoid syndrome patients.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Carcinoid syndrome is one of the functional neuroendocrin tumor symptom. It is a very rare disease and alittle known about this syndrome. We aimed a study that evaluating general characteristics and prognostic factors onsurvival in NET patients diagnosed with carcinoid syndrome.Methods: All patients diagnosed with neuroendocrine tumor were retrospectively reviewed in our institution. Thepatients diagnosed carsinoid syndrome were included in this study. General characteristics were recorded. Prognosticfactors on survival were analysed with Cox regression. Kaplan Meier method was used for overall survival.Results: Among 450 patients diagnosed neuroendocrine tumor in our hospital, 29 of them (6.4%) were presented withcarcinoid syndrome. The univariate analysis revealed that age, high tumor grade and ki67 score were correlated withpoor overall survival and the multivariate analyses revealed that older age were correlated with poor overall survival.The median OS were 61 months in all grades and 64 months for grade 1 tumors, 45 (13-76) months for grade 2 tumors,5 months for grade 3 tumors and there were statistically significant difference (p=0.007).Conclusion: Age, grade, ki67 score are important prognostic factor. Age is an independent prognostic factor that affecting survival in carcinoid syndrome patients.

🔖

Bu Makaleye Atıf Yap

ABDULREZZAK, Ü., İNANÇ, M., GÜRSOY, Ş., DURSUN, H., DOĞAN, E., ÖZKAN, M., SÖZÜER, E., BAYRAM, F., ÖZTÜRK, F., SEZGİN, G. C., YURCİ, A. (2022). General Characteristics and Prognostic Factors on Survival in Neuroendocrine Tumor Patients Diagnosed with Carcinoid Syndrome: Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 3, 347–352. https://ajindex.com/articles/508666

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Charles W. Kimbrough, Eliza W. Beal, Mary E. Dillhoff, Carl R. Schmidt, Timothy M. Pawlik, Alexandra G. Lopez-Aguiar et al., Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection, Surgery, 2018;10:25
  2. Ozaslan E, Bayram F, Karaca H, Gursoy S, Ozturk F, Sozuer E et al., Best Prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single- center study. Turk J Gastroenterol 2016;27:509–14
  3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72
  4. Beilei C, Broder MS, Eunice C,Yan T, Metz TC, Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors, World J Gastroenterol 2017;23:7283–91
  5. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525–34
  6. Grozinsky-Glasberg S, GrossmanAB&GrossDJ, Carcinoid heart disease: from pathophysiology to treatment – ‘something in the way it moves’. Neuroendocrinology 2015;101:263–73 7. Wouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, Richard A Feelders and Wouter W de Herder, Effect of hormone secretory syndromes on neuroendocrine tumor prognosis, Endocrine Realated Cancer 2017:24;R261–R274
  7. Bosman FT (2010). World Health Organization; International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer
  8. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–33
  9. Kirshbom, P.M., Kherani, A.R., Onaitis, M.W. et al, Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998;124:1063–1070
  10. Jerome M Feldman, R. Scott Jones, Carcinoid syndrom from gastrointestinal carcinoids without liver metastasis, Ann Surg 1982;196:1
  11. Haq AU, Yook CR, Hiremath V, Kasimis BS. Carcinoid syndrome in the absence of liver metastasis: A case report and review of literature. Med Pediatr Oncol 1992;20:221–3
  12. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–9